Terms: = Prostate cancer AND HER1, YOR227W
27 results:
1. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
2. Decline in arylsulfatase B expression increases EGFR expression by inhibiting the protein-tyrosine phosphatase SHP2 and activating JNK in prostate cells.
Bhattacharyya S; Feferman L; Han X; Ouyang Y; Zhang F; Linhardt RJ; Tobacman JK
J Biol Chem; 2018 Jul; 293(28):11076-11087. PubMed ID: 29794138
[TBL] [Abstract] [Full Text] [Related]
3. Assessment of the impact of manufacturing changes on the physicochemical properties and biological activity of her1-ECD vaccine during product development.
Garcia Duardo K; Prieto Curbelo Y; Raymond Pous J; Rabasa Legón EY; Ramírez BS; Hernández KR; Castillo Vitoch A
Vaccine; 2015 Aug; 33(35):4292-9. PubMed ID: 26003492
[TBL] [Abstract] [Full Text] [Related]
4. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.
Ishikawa T; Seto M; Banno H; Kawakita Y; Oorui M; Taniguchi T; Ohta Y; Tamura T; Nakayama A; Miki H; Kamiguchi H; Tanaka T; Habuka N; Sogabe S; Yano J; Aertgeerts K; Kamiyama K
J Med Chem; 2011 Dec; 54(23):8030-50. PubMed ID: 22003817
[TBL] [Abstract] [Full Text] [Related]
5. Vandetanib: first global approval.
Commander H; Whiteside G; Perry C
Drugs; 2011 Jul; 71(10):1355-65. PubMed ID: 21770481
[TBL] [Abstract] [Full Text] [Related]
6. Molecular oncogenesis of prostate adenocarcinoma: role of the human epidermal growth factor receptor 2 (HER-2/neu).
Neto AS; Tobias-Machado M; Wroclawski ML; Fonseca FL; Pompeo AC; Del Giglio A
Tumori; 2010; 96(5):645-9. PubMed ID: 21302606
[TBL] [Abstract] [Full Text] [Related]
7. Preparation, biological evaluation, and pharmacokinetics of the human anti-her1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma.
Nayak TK; Garmestani K; Baidoo KE; Milenic DE; Brechbiel MW
J Nucl Med; 2010 Jun; 51(6):942-50. PubMed ID: 20484421
[TBL] [Abstract] [Full Text] [Related]
8. PET imaging of her1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
[TBL] [Abstract] [Full Text] [Related]
9. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
Qi W; Cooke LS; Stejskal A; Riley C; Croce KD; Saldanha JW; Bearss D; Mahadevan D
BMC Cancer; 2009 May; 9():142. PubMed ID: 19432987
[TBL] [Abstract] [Full Text] [Related]
10. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications.
Armengol G; Rojo F; Castellví J; Iglesias C; Cuatrecasas M; Pons B; Baselga J; Ramón y Cajal S
Cancer Res; 2007 Aug; 67(16):7551-5. PubMed ID: 17699757
[TBL] [Abstract] [Full Text] [Related]
11. Is YKL-40 a new therapeutic target in cancer?
Johansen JS; Jensen BV; Roslind A; Price PA
Expert Opin Ther Targets; 2007 Feb; 11(2):219-34. PubMed ID: 17227236
[TBL] [Abstract] [Full Text] [Related]
12. The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.
Al Sarakbi W; Mokbel R; Salhab M; Jiang WG; Reed MJ; Mokbel K
Anticancer Res; 2006; 26(6C):4985-90. PubMed ID: 17214375
[TBL] [Abstract] [Full Text] [Related]
13. The role of her1-HER4 and EGFRvIII in hormone-refractory prostate cancer.
Edwards J; Traynor P; Munro AF; Pirret CF; Dunne B; Bartlett JM
Clin Cancer Res; 2006 Jan; 12(1):123-30. PubMed ID: 16397033
[TBL] [Abstract] [Full Text] [Related]
14. Molecular profile of androgen-independent prostate cancer xenograft LuCaP 23.1.
Fina F; Muracciole X; Rocchi P; Nanni-Métellus I; Delfino C; Daniel L; Dussert C; Ouafik L'; Martin PM
J Steroid Biochem Mol Biol; 2005 Sep; 96(5):355-65. PubMed ID: 16043352
[TBL] [Abstract] [Full Text] [Related]
15. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
Chinnaiyan P; Huang S; Vallabhaneni G; Armstrong E; Varambally S; Tomlins SA; Chinnaiyan AM; Harari PM
Cancer Res; 2005 Apr; 65(8):3328-35. PubMed ID: 15833866
[TBL] [Abstract] [Full Text] [Related]
16. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.
Wiseman SM; Makretsov N; Nielsen TO; Gilks B; Yorida E; Cheang M; Turbin D; Gelmon K; Huntsman DG
Cancer; 2005 May; 103(9):1770-7. PubMed ID: 15770691
[TBL] [Abstract] [Full Text] [Related]
17. Targeting c-erbB2 and other receptors of the c-erbB family: rationale and clinical applications.
Bianco AR
J Chemother; 2004 Nov; 16 Suppl 4():52-4. PubMed ID: 15688610
[TBL] [Abstract] [Full Text] [Related]
18. HER2/HER3 heterodimers in prostate cancer: Whither her1/EGFR?
Freeman MR
Cancer Cell; 2004 Nov; 6(5):427-8. PubMed ID: 15542423
[TBL] [Abstract] [Full Text] [Related]
19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract] [Full Text] [Related]
20. The HER receptor family: a rich target for therapeutic development.
Mass RD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):932-40. PubMed ID: 14967453
[TBL] [Abstract] [Full Text] [Related]
[Next]
